Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

By Henry David H.   Gordan Lucio N.   Charu Veena   Wilhelm Francois E.   Williams Denise   Xie John   Woodman Richard C.  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1403-1413

Informa Healthcare

Access to resources Recommend Favorite

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia**

By Hernandez Enrique   Ganly Peter   Charu Veena   DiBenedetto Joseph   Tomita Dianne   Lillie Tom   Taylor Kerry    

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2109-2120

Informa Healthcare

Access to resources Recommend Favorite

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia

By Ben-Hamadi R.   Duh M. S.   Aggarwal J.   Henckler A.   Mckenzie R. S.   Tak Piech C.  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1677-1682

Informa Healthcare

Access to resources Recommend Favorite

Chemotherapy-induced anemia: the story of darbepoetin alfa

By Vansteenkiste Johan   Wauters Isabelle   Elliott Steven   Glaspy John   Hedenus Michael  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 325-337

Informa Healthcare

Access to resources Recommend Favorite

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 361-8609, Iss. 10, 2015-10 ,pp. : 877-881

John Wiley & Sons Inc

Access to resources Recommend Favorite